BioSyent Inc.

Climate Impact & Sustainability Data (2022)

Initiated a quarterly dividend to shareholders.
Feramax® brand named the #1 Pharmacist and Physician recommended over-the-counter oral iron supplement brand in Canada for the seventh consecutive year.

Renewal of Normal Course Issuer Bid for a 5th consecutive year, reducing outstanding share count by approximately 16%.

Inflation, rising interest rates, supply chain strains, and the war in Ukraine.
Double-digit sales declines in the Company’s International Pharmaceutical Business and Legacy Business.
Reorganization proceedings with self-administration were opened in February 2023 under the Austrian Insolvency Code for the assets of the supplier of the Cathejell® product.

Strong balance sheet, cash position and zero debt.
Continued investment in long-term growth through the launch of new products and expansion of the field salesforce.
Monitoring and adjusting the total net monetary liability balance; using Dual Currency Deposits, foreign exchange options, and forward purchase contracts to manage foreign exchange transaction exposure.
Maximizing the interest income earned on excess funds while maintaining the liquidity necessary to conduct operations.